多発性骨髄腫患者におけるダラツムマブ皮下投与時の有害事象に対するジフェンヒドラミンとレボセチリジン前処置の比較

• Material Type: 記事
• Title: 多発性骨髄腫患者におけるダラツムマブ皮下投与時の有害事象に対するジフェンヒドラミンとレボセチリジン前処置の比較
• Author Heading: 末廣 直哉; 長島 彩乃; 西川 はる; 鈴川 真由; 櫻井 洋臣; 村松 博; 青森 達; 大谷 壽一
• Publication Date: 2023-08-10
• Publication Date (W3CDTF): 2023-08-10
• Periodical title: 医療薬学
• No. or year of volume/issue: 49 8
• Volume: 49
• Issue: 8
• Pages: 303-309
• Publication date of volume/issue (W3CDTF): 2023-08-10
• ISSN (Periodical Title): 1346342X
• ISSN-L (Periodical Title): 1346342X
• Publication (Periodical Title): Japanese Society of Pharmaceutical Health Care and Sciences
• Text Language Code: ja
• Subject Heading: daratumumab; antihistamine; levocetirizine; infusion reaction; drowsiness
• Target Audience: 一般
• DOI: 10.5649/jjphcs.49.303; https://doi.org/10.5649/jjphcs.49.303
• Related Material (URI): https://www.jstage.jst.go.jp/article/jjphcs/49/8/49_303/_pdf; https://search.jamas.or.jp/link/ui/2023282912
• References: Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions; https://cir.nii.ac.jp/crid/1360020001687747456; Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites; https://cir.nii.ac.jp/crid/1360292619463358848; Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma; https://cir.nii.ac.jp/crid/1360301475091635328; Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial; https://cir.nii.ac.jp/crid/1360855569810943488; Pharmacology of antihistamines; https://cir.nii.ac.jp/crid/1360855570735241472; Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications; https://cir.nii.ac.jp/crid/1360864423858448256; Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma; https://cir.nii.ac.jp/crid/1361981470526518144; Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study; https://cir.nii.ac.jp/crid/1362262943877346432; Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis; https://cir.nii.ac.jp/crid/1362544418447561856; Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma; https://cir.nii.ac.jp/crid/1362544421033650944; Evaluation of the safety and efficacy of daratumumab outside of clinical trials; https://cir.nii.ac.jp/crid/1363951794767046400; Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial; https://cir.nii.ac.jp/crid/1364233269854961664; 日本人の再発または難治性多発性骨髄腫におけるDaratumumabの安全性に関する後方視的検討とInfusion Related Reaction発現リスク因子の探索; https://cir.nii.ac.jp/crid/1390286981358561536; フェキソフェナジンあるいはベポタスチンの前投薬によるリツキシマブ投与時のinfusion reaction発現抑制効果; https://cir.nii.ac.jp/crid/1390848250127668480
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• Summary, etc.: <p>Subcutaneous daratumumab DARA-SC is superior to intravenous daratumumab with a significantly shorter treatment time for multiple myeloma. To preven...